ReviewClinical journal of the American Society of Nephrology : CJASN2026
Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- HDL from patients with type 2 diabetes impairs endothelial function by inducing ferroptosis via nuclear receptor coactivator 4.Journal of lipid research · 2026Article
- Ultra-Processed Foods, MASLD, and Cognitive Aging: A Processing-Centered Gut-Liver-Brain Axis Perspective.Nutrients · 2026Review
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4.Cardiovascular diabetology · 2026Article
- The association between modified cardiometabolic index and cardiovascular disease risk in adults with early cardiovascular-kidney-metabolic syndrome: a prospective cohort study.BMC cardiovascular disorders · 2026Article
- Association of the C-reactive protein-triglyceride-glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studies.Cardiovascular diabetology · 2026Article
- Acetylation in renal physiology and pathophysiology.Frontiers in pharmacology · 2025Review
- The roles of advanced glycation end products in cardiovascular diseases: from mechanisms to therapeutic strategies.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome is a new term indicating a health condition that emphasizes the interconnection of diabetes (type 2 diabetes [T2D]), insulin resistance (IR), CKD, and cardiovascular disease; the pathogenic links between these conditions seem to start with IR/T2D. The incidence and prevalence of this condition are increasing in parallel with the contemporary Western culture consumption of ultra-processed foods. Thermic processing of food increases the formation of pro-oxidant and proinflammatory advanced glycation end products (AGEs), which are partially absorbed into the body increasing the body pool of AGEs, which eventually produces chronic tissue injury, including IR. In this article, we review the literature and present experimental and human data supporting the hypothesis that AGEs in food are major contributory factors to toxicity of ultra-processed foods. We postulate that although hyperglycemia accompanying the diabetic state increases endogenous AGE production, ingestion of these compounds in food may also initiate oxidative stress that eventually causes IR and T2D. Several small clinical trials have studied the effect of dietary AGE intake restriction over variable periods of time, and most of them have demonstrated significant reduction not only in circulating markers of AGEs but also in markers of inflammation and oxidative stress in healthy as well as in CKM subjects. An AGE-restricted diet has also been shown to improve markers of IR. Final proof of a therapeutic role for the low AGE diet will require large, prospective, and randomized clinical trials, which may be challenging to accomplish. We believe, however, that current available data make it reasonable and prudent to advise limitation of dietary AGEs in the general population as well as in CKM patients. Importantly, the simple changes in culinary techniques suggested here can markedly affect AGE content in food and be incorporated as meal patterns consistent with most currently available recommendations promoting CKM health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.